Loading…

Neogen CorpNEOGCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of food safety and animal health testing products, including diagnostics, genomics and sanitation solutions.

Momentum strong 68
Mkt cap
$2.42B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$34.8M
20-day average traded
Fwd P/E
32.6×
forward earnings
ROIC−WACC
-12.2 pp
WACC 12.2%
Hurdle
n/a
no reverse DCF
Next earnings
57 days
14 Jan 2027
Close · USD$11.08
1D+1.6%
1W-4.5%
1M-5.5%
3M-6.3%
6M+25.5%
YTD+58.5%
1Y+72.6%
ATR %4.3%
Beta1.37
52w lowhigh22.3% off high

What Neogen does

Maker of food safety and animal health testing products, including diagnostics, genomics and sanitation solutions.

Sells test kits and the readers that go with them, so most income is repeat purchases of single-use kits as customers test every batch of product. The 2022 combination with 3M's food-safety business greatly enlarged it and brought debt and integration work.

Products and services

  • Food safety diagnostic test kits
  • Animal health/genomics testing
  • Sanitation/hygiene monitoring products
  • Veterinary instruments

Customers

  • Food & beverage manufacturers
  • Farms/agribusiness
  • Veterinarians

Where it sits in the supply chain

  • Life sciences/diagnostics
  • Food safety & animal health testing
  • Diagnostic kits, genomics, sanitation…

What could go right

  • Food safety regulation tightening
  • Animal genomics testing growth

What could go wrong

  • Agricultural customer spending cyclicality
  • Post-merger integration risk

Moat: narrow (regulatory licence, switching costs, brand). Established brand and regulatory-validated test kits embedded in customers' food-safety and farm workflows.

Headquarters: Lansing, Michigan · Founded: 1982 · Employees: 2,636

Named competitors

Neogen at a glance

Size Neogen (NEOG) is a United States Health Care company (Medical Specialties) with a market value of $2.42B, the 1659th largest of 3,085 United States companies the cockpit tracks. Shares closed at $11.08 on 18 Nov 2026.

Performance Over six months the shares gained 25.5%, against -0.3% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue fell 0.3% over the last twelve months (peer median +5.1%); the operating margin is 0.0% (peer median 8.3%).

Valuation It trades at 32.6× forward earnings against a peer median of 24.2× (6th most expensive of 18).

Capital Return on invested capital runs 12.2 points below its cost of capital (12.2% WACC).

Short interest Short interest is 5.8% of the free float (30 Oct 2026).

Next results Next results expected around 14 Jan 2027 (exchange calendar; dates can move).

Relative performance

10012014016021 May 202621 Aug 202618 Nov 2026NEOG 125Peer median 101
Six months, rebased to 100: Neogen against the median of its 20 peers (local-currency closes).

Neogen financials

Reported figures in USD; fiscal year ends 2026-05-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$884M$870M$895M$924M$822M
Revenue growth—-3%-3%+12%—
Gross profit$327M$408M$421M$463M$406M
EBITDA$118M$107M$135M$199M$126M
Net income-$56.1M-$7.90M-$1.09B-$9.42M-$22.9M
Free cash flow$49.7M$31.9M-$48.4M-$76.7M-$24.7M
Capital expenditure$35.5M$51.3M$105M$111M$65.8M
Total debt$774M$812M$913M$906M$898M

Quarterly statements and history in the cockpit →

Neogen competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%+20%002901MOVE300529EKTA-BEBO6880292276OBCKMETNCELCDRW86951ESTACOTNATRCVCYTBONEX688114MEDAFXNEOG6-month return →1-month return →
Up and to the right = strong over both horizons. Neogen is the large dot.

Fundamentals: revenue growth against valuation

0%+20%0×100×200×002901MOVE300529EKTA-BEBO2276OBCKMETN6951COTNATRCVCYTBONEXMEDAFXNEOGRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Neogen is the large dot.

Neogen competitors and peer comparison

Head to head with its named competitors (NEOG vs TMO vs IDXX vs BIO)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Neogen NEOG$2.42B+25%0%0%32.6×n/a
Thermo Fisher Scientific TMO$257B+53%+8%19%25.7×21.3%
Idexx Laboratories IDXX$55.0B+26%+12%32%42.9×29.0%
Bio-Rad Laboratories BIO$10.1B+29%+1%9%34.6×26.0%
Zoetis ZTS$34.8B+7%+1%37%13.8×-2.9%

How Neogen compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Neogen against its 20 peers (data as of 18 Nov 2026)
MeasureNEOGPeer medianRank in peer set
1-month return-5.5%-1.6%8th lowest of 21
6-month return+25.5%-0.3%3rd highest of 21
Distance from 52-week high-22.3%-27.0%9th highest of 21
Revenue growth (TTM)-0.3%+5.1%4th lowest of 20
Operating margin0.0%8.3%4th lowest of 20
Forward P/E32.6×24.2×6th most expensive of 18
ROIC minus cost of capital-12.2 pp-0.6 pp2nd lowest of 20
EV / EBITDA25.7×15.8×5th most expensive of 13
Net debt / EBITDA5.1×0.4×2nd most indebted of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Neogen NEOGUnited States$2.42B+25%0%0%32.6×n/an/a
Double Medical Technology 002901.SZChina$2.43B-2%+13%26%24.2×7.6%+10.4%
Medacta MOVE.SWSwitzerland$2.48B-28%+8%15%24.0×n/an/a
Jafron Biomedical 300529.SZChina$2.35B+3%+1%37%24.3×6.1%+0.6%
Elekta EKTA-B.STSweden$2.35B0%-7%6%15.3×10.7%+4.0%
EBOS EBO.AXAustralia$2.50B+7%+3%3%15.7×4.7%+6.8%
Micro-Tech (Nanjing) 688029.SSChina$2.33B0%+6%18%28.1×11.9%+19.2%
Shanghai Conant Optical 2276.HKHong Kong$2.25B-17%+8%29%22.1×-1.1%+14.1%
Ottobock SE & Co. KGaA OBCK.DEGermany$2.65B-30%+5%17%12.3×-1.2%+8.0%
Metall Zug METN.SWSwitzerland$2.19B+20%0%-10%139.8×n/an/a
Celcuity CELCUnited States$2.73B-60%n/an/an/an/an/a
Draegerwerk AG & Co. KGaA DRW8.DEGermany$2.13B+25%+5%7%10.2×-10.2%+0.4%
JEOL 6951.TJapan$2.12B-2%-15%12%15.5×22.2%+10.2%
Establishment Labs ESTAUnited States$2.11B+1%+38%-7%n/an/an/a
COMET COTN.SWSwitzerland$2.78B-15%-3%6%32.8×n/an/a
AtriCure ATRCUnited States$2.82B+91%+14%3%212.4×54.2%+20.9%
Veracyte VCYTUnited States$2.06B-43%+18%16%17.1×18.0%+34.5%
Bonesupport BONEX.STSweden$2.06B+21%+25%25%61.5×12.6%+45.4%
MGI Tech 688114.SSChina$3.06B-4%+2%-7%n/a43.7%-0.1%
Medartis MED.SWSwitzerland$1.86B+47%+30%2%72.8×n/an/a
Carl Zeiss Meditec AFX.DEGermany$3.17B+22%0%8%24.4×12.5%+10.8%

Questions

Who are Neogen's main competitors?
Named competitors: Thermo Fisher Scientific (TMO), IDEXX Laboratories (IDXX), Bio-Rad Laboratories (BIO), Zoetis (ZTS). The cockpit's measured peer set (industry) also includes Double Medical Technology (002901.SZ), Medacta (MOVE.SW), Jafron Biomedical (300529.SZ), Elekta (EKTA-B.ST), EBOS (EBO.AX), Micro-Tech (Nanjing) (688029.SS).
Is Neogen expensive compared with its peers?
On forward p/e it trades at 32.6× against a peer median of 24.2×, 6th most expensive of 18 in its peer set.
How has Neogen stock performed?
Over six months to 18 Nov 2026 the shares returned +25.5% against -0.3% for the median peer; over one year +72.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.